NETosis in Neurodegeneration

Migration, Crosslink

📖

NETosis in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-netosis-neurodegeneratio

📖 Wiki Page

mechanism976 wordssynced 2026-04-02

NETosis in Neurodegeneration

Related Mechanisms: [Neuroinflammation](/mechanisms/neuroinflammation), [Microglial Activation](/mechanisms/microglial-phagocytosis), [Blood-Brain Barrier Breakdown](/mechanisms/blood-brain-barrier-breakdown)

Overview

NETosis is a specialized form of cell death in neutrophils that results in the release of neutrophil extracellular traps (NETs) — webs of chromatin fibers decorated with antimicrobial proteins including neutrophil elastase (NE), myeloperoxidase (MPO), and histones[@brinkmann2004]. Originally described as a defense mechanism against pathogens, dysregulated NETosis has been increasingly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@caielli2022].

Molecular Mechanism

Classical NETosis Pathway

Neutrophil activation triggers a cascade of events leading to NET release:

Neutrophil activation — via receptors (TLRs, complement receptors, Fcγ receptors) or pathogens

NADPH oxidase activation — produces [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)

Peptidylarginine deiminase 4 (PAD4) activation — citrullinates histones

Chromatin decondensation — nuclear membrane breakdown

NET release — chromatin and associated proteins expelled extracellularly[@papayannopoulos2017]

NETosis Pathway in Neurodegeneration

...

NETosis in Neurodegeneration

Related Mechanisms: [Neuroinflammation](/mechanisms/neuroinflammation), [Microglial Activation](/mechanisms/microglial-phagocytosis), [Blood-Brain Barrier Breakdown](/mechanisms/blood-brain-barrier-breakdown)

Overview

NETosis is a specialized form of cell death in neutrophils that results in the release of neutrophil extracellular traps (NETs) — webs of chromatin fibers decorated with antimicrobial proteins including neutrophil elastase (NE), myeloperoxidase (MPO), and histones[@brinkmann2004]. Originally described as a defense mechanism against pathogens, dysregulated NETosis has been increasingly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@caielli2022].

Molecular Mechanism

Classical NETosis Pathway

Neutrophil activation triggers a cascade of events leading to NET release:

Neutrophil activation — via receptors (TLRs, complement receptors, Fcγ receptors) or pathogens

NADPH oxidase activation — produces [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)

Peptidylarginine deiminase 4 (PAD4) activation — citrullinates histones

Chromatin decondensation — nuclear membrane breakdown

NET release — chromatin and associated proteins expelled extracellularly[@papayannopoulos2017]

NETosis Pathway in Neurodegeneration

Mermaid diagram (expand to render)

Vital NETosis

An alternative, non-lytic pathway where NETs are released from viable neutrophils, involving nuclear envelope budding and nuclear-derived vesicles[@yousefi2020].

NET Components

| Component | Function |
|-----------|----------|
| DNA backbone | Structural scaffold for NETs |
| Neutrophil elastase (NE) | Proteolytic degradation of pathogens |
| Myeloperoxidase (MPO) | H2O2-dependent antimicrobial activity |
| Citrullinated histones | Promote chromatin decondensation |
| LL37 | Antimicrobial peptide |
| Cathepsin G | Proteolytic activity |

NETosis in Alzheimer's Disease

Evidence

Multiple studies have documented elevated NET markers in AD patients:

Serum NET markers: Higher levels of NET-associated proteins (NE, MPO, citrullinated histone H3) in AD patients compared to controls[@zhou2023]
Brain tissue: Presence of NETs and neutrophil infiltration in AD brain regions[@ryu2022]
Animal models: Neutrophil depletion or NET inhibition reduces amyloid pathology and improves cognitive function[@zhang2020]

Mechanisms

Amyloid-β induced NETosis: [Aβ](/proteins/amyloid-beta) peptides can directly activate neutrophils to release NETs[@ito2021]

Neuroinflammation amplification: NETs activate [microglia](/cell-types/microglia-neuroinflammation) through TLRs and promote pro-inflammatory cytokine production[@hu2022]

[Blood-brain barrier](/entities/blood-brain-barrier) disruption: NET components can damage endothelial cells and increase BBB permeability[@cui2021]

Synaptic damage: NET-associated proteases can degrade synaptic proteins[@gomez2021]

Therapeutic Implications

PAD4 inhibitors — reduce NET formation
NE inhibitors — block NET-mediated damage
Anti-NET antibodies — neutralize NET components
DNase therapy — degrade existing NETs

NETosis in Parkinson's Disease

Evidence

Elevated NET markers in PD patient serum and cerebrospinal fluid[@szekeres2023]
Neutrophil dysfunction in PD patients showing increased propensity for NETosis
Post-mortem brain tissue revealing NET components in substantia nigra[@kwon2023]

Mechanisms

[Alpha-synuclein](/proteins/alpha-synuclein)-induced NETosis: α-syn aggregates can trigger NET release from neutrophils[@kim2022]

LRRK2 mutations: LRRK2 G2019S associated with enhanced neutrophil activation and NETosis[@moehle2022]

Dopaminergic neuron vulnerability: NETs may preferentially damage dopaminergic [neurons](/entities/neurons)

Microglial activation: NET-mediated microglial priming creates a pro-inflammatory environment[@garcia2023]

NETosis in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Elevated NET markers in ALS patients and mouse models
NETs contribute to motor neuron injury
NET inhibition improves survival in animal models[@fang2021]

Multiple Sclerosis (MS)

NETs detected in active MS lesions
Associated with disease progression
Potential therapeutic target[@gulce2022]

Therapeutic Strategies

Small Molecule Inhibitors

| Drug/Compound | Target | Status |
|---------------|--------|--------|
| Cl-amidine | PAD4 | Preclinical |
| GSK-484 | PAD4 | Preclinical |
| Sivelestat | NE | Approved for ARDS |
| Omega-3 fatty acids | NETosis modulation | Clinical trials |

Biological Approaches

Anti-NET antibodies: Neutralize NET components
DNase I: Degrade NET DNA
Neutrophil depletion: Reduce NET source (experimental)
TLR inhibitors: Block NET-mediated inflammation

Research Challenges

NET detection in brain: Technical difficulties imaging NETs in CNS tissue

Species differences: Mouse vs human neutrophil responses

Chronic vs acute NETosis: Long-term effects in neurodegeneration

Therapeutic window: Balancing antimicrobial defense with NET inhibition

Key Researchers and Institutions

[Mayo Clinic](/institutions/mayo-clinic) — Dr. Aaron Courties
[University of Pennsylvania](/university-of-pennsylvania) — Dr. Carlos Gilfillan
[University of Bonn](/institutions/university-of-bonn) — Dr. Mario Njoku

Cross-References

[Neuroinflammation](/mechanisms/neuroinflammation)
[Microglial Activation](/mechanisms/microglial-phagocytosis)
[Alzheimer's Disease Pathophysiology](/diseases/alzheimers-disease)
[Parkinson's Disease Pathophysiology](/diseases/parkinsons-disease)
[Blood-Brain Barrier Breakdown](/mechanisms/blood-brain-barrier-breakdown)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

[Neutrophils and NETosis in Alzheimer's disease: Unraveling pathogenic mechanisms and novel therapeutic targets.](https://pubmed.ncbi.nlm.nih.gov/40972402/) (2025 Nov) - Biomed Pharmacother
[Role of Histone Deacetylase Inhibitor in Diabetic Painful Neuropathy.](https://pubmed.ncbi.nlm.nih.gov/37875708/) (2024 Apr) - Mol Neurobiol

References

Unknown (n.d.)

📖 View canonical wiki page →

Related Entities

mechanisms-netosis-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-netosis-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-66e961fd9679
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-netosis-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

552

Outgoing

713

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NETosis in Neurodegeneration

NETosis in Neurodegeneration

Overview

Molecular Mechanism

Classical NETosis Pathway

NETosis Pathway in Neurodegeneration

NETosis in Neurodegeneration

Overview

Molecular Mechanism

Classical NETosis Pathway

NETosis Pathway in Neurodegeneration

Vital NETosis

NET Components

NETosis in Alzheimer's Disease

Evidence

Mechanisms

Therapeutic Implications

NETosis in Parkinson's Disease

Evidence

Mechanisms

NETosis in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis (MS)

Therapeutic Strategies

Small Molecule Inhibitors

Biological Approaches

Research Challenges

Key Researchers and Institutions

Cross-References

See Also

External Links

Recent Research (2024-2026)

References

💬 Discussion